Heat Biologics’ CSO to Participate in the 27th Annual Cancer Progress Conference by Defined Health
DURHAM, N.C., March 09, 2016 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient’s immune system against cancer, announced that Taylor Schreiber, M.D., Ph.D., Heat’s Chief Scientific Officer, will participate in the 27th Annual Cancer Progress Conference by Defined Health being held in New York City. Dr. Schreiber will serve as a speaker on a panel entitled “Immuno-Oncology I: Attacking Cancer Antigens – Exploiting off-the-Shelf and Personalized Vaccines and Triggering of Immunogenic Cell Death,” which takes place today at 9:15 a.m. Eastern Time.
Cancer Progress is an oncology conference that invites a discussion of scientific progress within the context of development, regulatory, clinical, commercial and investment perspectives. The conference spans over two days, encompassing interactive dialogue among industry professionals. For more information regarding the conference and agenda, please visit www.cancerprogressbydh.com.
About Heat Biologics, Inc.
Heat Biologics, Inc. (Nasdaq:HTBX) is an immuno-oncology company developing novel therapies that activate a patient’s immune system against cancer. Heat’s highly specific T cell-stimulating platform technologies, ImPACT and ComPACT, form the basis of its product candidates. These platforms, in combination with other therapies, such as checkpoint inhibitors, are designed to address three distinct but synergistic mechanisms of action: robust activation of CD8+ “killer” T cells (one of the human immune system’s most potent weapons against cancer); reversal of tumor-induced immune suppression; and T cell co-stimulation to further enhance patients’ immune response. Currently, Heat is conducting a Phase 2 trial with its HS-410 (vesigenurtacel-L) in patients with non-muscle invasive bladder cancer (NMIBC) and a Phase 1b trial with its HS-110 (viagenpumatucel-L) in combination with an anti-PD-1 checkpoint inhibitor to treat patients with non-small cell lung cancer (NSCLC). For more information, please visit www.heatbio.com.
CONTACT: Heat Biologics, Inc. Jennifer Almond Investor and Media Relations 919-240-7133 investorrelations@heatbio.com
Released March 9, 2016